OmniRayn
← All repurposing reports
S2 (505(b)(2))

Idiopathic Pulmonary Fibrosis;Non-Specific Interstitial Pneumonia

Known, approved drugs ranked as repurposing candidates for Idiopathic Pulmonary Fibrosis;Non-Specific Interstitial Pneumonia — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1clarithromycinApproved
  2. 2atracuriumApproved
  3. 3idarubicinApproved
  4. 4amiodaroneApproved
  5. 5oxaprozinApproved
  6. 6acetylcholineApproved
  7. 7phensuximideApproved
  8. 8auranofinApproved

Full dossier — 146 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950